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Purpose: To compare self-complementary (sc) and single-stranded (ss) adeno-associated viral 2/5 (AAV2/5) vectors for
retinal cell transduction in the dog when delivered by subretinal injection.
Methods: ScAAV2/5 and ssAAV2/5 vectors encoding enhanced green fluorescent protein (GFP) under control of the
chicken beta actin promoter were prepared to the same titer. Equal amounts of viral particles were delivered into the
subretinal spaces of both eyes of two dogs. In each dog, one eye received the scAAV2/5 and the other the ssAAV2/5. In
vivo expression of GFP was monitored ophthalmoscopically. The dogs were sacrificed, and their retinas were examined
by fluorescent microscopy and immunohistochemistry to determine GFP expression patterns and to assay for glial
reactivity.
Results: GFP expression in the scAAV2/5 injected eyes was detectable at a much earlier time point than in the ssAAV2/5
injected eyes. Expression of GFP was also at higher levels in the scAAV2/5-injected eyes. Expression levels remained
stable for the seven month duration of the study. The types of cells transduced by both vectors were similar; there was
strong reporter gene expression in the RPE and photoreceptors, although not all cones in the transduced area expressed
GFP. Some horizontal and Müller cells were also transduced.
Conclusions: When delivered by subretinal injection in the dog, scAAV2/5 induces faster and stronger transgene
expression than ssAAV2/5. The spectrum of retinal neurons transduced is similar between the two vectors. These results
confirm in a large animal model those previously reported in the mouse. ScAAV2/5 shows promise for use in the treatment
of conditions where a rapid transgene expression is desirable. Furthermore, it may be possible to use a lower number of
viral particles to achieve the same effect compared with ssAAV2/5 vectors.
The  many  different  forms  of  retinal  dystrophy  that
spontaneously occur in the dog have made this species an
extremely  valuable  large  animal  model  for  therapeutic
interventions. One example is the RPE65 mutant dog model
of Leber Congenital Amaurosis that has been used to evaluate
gene therapy approaches before human clinical trials [1,2]. In
addition to the RPE65 mutant dog there are dog models of
autosomal recessive retinitis pigmentosa due to different gene
mutations  [3-5],  autosomal  dominant  retinitis  pigmentosa
[6],  X-linked  RP  [7],  cone-rod  dystrophies  [8,9],  and
achromatopsia [10]. Several of these models are being used
to develop and test gene therapy approaches that are ultimately
aimed  for  use  in  human  patients.  Transduction  of
photoreceptor  or  retinal  pigment  epithelial  cells  has  been
successfully  achieved  with  adeno-associated  viral  (AAV)
vectors, partly due to their ability to transduce nondividing
cells, the resulting long-term expression of the transgene, and
the lack of problems associated with immune responses [11].
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There are some recognized drawbacks to the current AAV
vectors. One of which is the presence of a lag-phase before
transgene expression following cell infection with the vector.
One factor that contributes to the delay in AAV-introduced
transgene  expression  is  the  requirement  for  the  single-
stranded genome to be converted to double-stranded DNA in
the host nucleus [12-14]. A lag in transgene expression is
problematic  when  attempting  to  treat  rapidly  progressive
conditions, where an early onset of transgene expression is
particularly important for success of the therapy. One such
large animal example is the PDE6A mutant dog model of
autosomal recessive RP in which peak levels of rod apoptosis
have been detected at about four weeks of age [15]. This rapid
loss of photoreceptors has made gene replacement therapy in
this model challenging (SPJ, unpublished results). It is likely
that similar challenges could be faced when attempting to
rescue  rod  photoreceptors  in  human  RP  patients  with
mutations that result in a rapid loss of rod photoreceptors.
Recently self-complementary AAV (scAAV) vectors have
been developed that may overcome this rate-limiting step
[16]. ScAAV vectors consist of a single-stranded inverted-
repeat genome separated by a mutated terminal resolution site.
The insert is designed so that the DNA can fold on itself to
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1835produce a double stranded DNA version of the transgene,
without  requiring  DNA  synthesis.  ScAAV  vectors  have
improved transduction efficiency in several tissues, including
liver, muscle, CNS, bone marrow and the eye, compared to
single-stranded AAV (ssAAV) preparations (see [17] for a
review). In mice, a comparison of reporter gene expression in
the outer retina following subretinal injection has shown that
scAAV2 transgene expression is faster and stronger compared
with that achieved by the equivalent ssAAV2 vector [18]. A
study  comparing  multiple  AAV  serotypes  delivered  by
subretinal  injection  in  mice  showed  that  scAAV2/8
expressing green fluorescent protein (GFP) had faster and
stronger expression than the equivalent ssAAV2/8 construct.
A comparison between scAAV2/5 and ssAAV2/5 showed that
the self-complementary construct induced stronger reporter
gene expression, but with a similar time of onset, compared
with the equivalent single-stranded construct [19].
This study was undertaken to investigate how efficiently
a scAAV2/5 preparation transduces the canine outer retina in
comparison  to  a  ssAAV2/5  preparation.  It  showed  that
scAAV2/5 results in a faster turn on and stronger transgene
expression in the canine retina.
METHODS
Production of ssAAV2/5 and scAAV2/5: AAV vectors were
manufactured and purified by previously described methods
[20]. Vector titer was determined by real time PCR, and final
aliquots were resuspended in balanced salt solution (Alcon
Laboratories, Fort Worth, TX) containing 0.014% Tween-20.
The ssAAV and scAAV were type 2/5 vectors carrying the
enhanced GFP (eGFP) gene driven by the chicken beta actin
promoter. The scAAV2/5 construct had a titer of 0.5×1012
viral  particles  per  milliliter  (vp/ml)  and  the  ssAAV2/5
construct  was  prepared  to  the  same  titer.  Our  previous
unpublished  studies  showed  that  this  titer  of  sAAV2/5
delivered by subretinal injection in the dog results in outer
retinal GFP expression, which can be detected in vivo by our
imaging system.
Subretinal injections: Two normal adult crossbred dogs (a 35-
month-old  male  and  a  29-month-old  female)  that  were
produced as part of a breeding program at Michigan State
University were used in the experiment in compliance with
the ARVO statement for the Use of Animals in Ophthalmic
and Vision Research and approved by the institutional animal
care and use committee. Dogs were housed in the College of
Veterinary Medicine vivarium, at Michigan State University.
They were given ad libitum water and fed a mixture of Hill’s
Maintenance  (Hill’s  Pet  Nutrition  inc.  Topeka,  KS)  and
Purina Pro Plan (Purina-Nestle, St Louis, MO). They were
housed  under  12  h  light:dark  cycles.  Following  pupillary
dilation by application of a drop of topical tropicamide 1%
ophthalmic  drops  (Mydriacyl.  Alcon  Pharmaceuticals,  Ft.
Wayne, TX), both dogs underwent a full ophthalmoscopic
examination  (including  slit  lamp  biomicroscopy,  indirect
ophthalmoscopy and fundus photography) before the study.
For subretinal injection the anesthesia protocol used was to
premedicate  with  intramuscular  acepromazine  maleate
(Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO; 0.1–
0.3  mg/kg),  induce  with  intravenous  thiopental  sodium
(Pentothal, Hospira Inc., Lake Forest, IL; 6–12 mg/kg given
to effect) and maintain with inhaled isoflurane (Isoflo, Abbott
Laboratories, North Chicago, IL; 1 to 2%) delivered in oxygen
via an endotracheal tube. The eyes were prepared for aseptic
surgery  by  swabbing  the  ocular  surface  and  surrounding
adnexa with a 1:50 dilution of povidone-iodine solution. A
sterile fenestrated drape was applied and an eyelid speculum
inserted.  The  eye  was  manipulated  into  a  primary  gaze
position by the use of 4–0 silk (Ethicon, Inc., Piscataway, NJ)
stay sutures placed in the perilimbal conjunctiva. Under direct
observation  through  an  ophthalmic  operating  microscope
(Opmi6.  Carl  Zeiss  Meditech  Inc.,  Dublin,  CA)  and  a
Machemer  vitrectomy  lens  (Ocular  Instruments,  Bellevue,
WA) a subretinal injector (RetinaJect. SurModics Inc., Irvine,
CA) was used to deliver a subretinal injection [21]. Briefly,
the injector was introduced through the pars plana and, under
direct observation, was advanced across the vitreal cavity
toward  the  retinal  surface.  The  device  had  a  39  gauge
extendable cannula. This was extended to press on the retinal
surface. As the injection was made, the fluid pressure created
TABLE 1. DETAILS OF PRIMARY ANTIBODIES USED FOR IHC
Antibody Host Target cell Working dilution Source
Anti-GFP Rabbit Cells expressing GFP protein 1:5,000 Dr. Luc Berthiaume, University of Alberta, Alberta,
Canada
Human Cone Arrestin Rabbit Cone photoreceptors 1:100,000 Dr. Cheryl Craft & Xuemei Zhu, Mary Allen Lab,
Doheny Eye Institute, University of Southern
California, Los Angeles, CA
Protein Kinase C alpha Mouse Rod bipolar cells 1:200 BD Biosciences, PharMingen, Rockville, MD
PSD95 Mouse Rod spherules and cone
pedicles
1:100 Neuromab, University of California Davis, Davis,
CA
Calbindin Mouse Horizontal cells 1:1,000 Swant Immunochemicals, Bellinzona, Switzerland
Calretinin Rabbit Horizontal cells 1:1,000 Swant Immunochemicals, Bellinzona, Switzerland.
GFAP Rabbit Astrocytes and reactive
Müller glia
1:2,000 DakoCytomation, Carpinteria, CA
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1836a retinotomy. The injected fluid passed through the retinotomy
into the subretinal space and induced retinal detachment.
In each dog, the left eye was injected with 250 µl of
scAAV2/5-GFP vector at 0.5×1012 vp/ml. The right eye was
injected  with  250  µl  of  ssAAV2/5-GFP  at  the  same
concentration of viral particles. Injections were made in the
tapetal region in all eyes. Wide-angle fundus images were
captured before and after subretinal injection using a digital
fundus  camera  (RetCam  II.  Clarity  Medical  Systems,
Pleasanton, CA).
Post-operative analgesia was provided by intramuscular
administration  of  0.01  mg/kg  buprenorphine  (Torbugesic,
Fort Dodge Animal Health, Fort Dodge, IO). Topical broad
spectrum and steroid ophthalmic ointment (Neomycyn and
Polymyxin  B  Sulfates  and  Dexamethasone,  Alcon
Laboratories, Fort Wayne, TX) was placed in each eye after
surgery and three times daily for 4 days.
Ophthalmoscopic  monitoring:  The  dogs  had  full
ophthalmology examinations the day following surgery and
then every two days for the first week after injection and then
subsequently two times per week until euthanasia. Fundus
images  were  captured  at  every  examination,  and  the
fluorescein angiography settings of the fundus camera were
used to screen for GFP expression. To detect low levels of
fluorescence, we enhanced images for contrast and brightness
using Photoshop (Photoshop CS2, Adobe Systems Inc., San
Jose, CA).
Immunohistochemistry: Dogs were humanely euthanized with
an overdose of intravenous pentobarbital sodium (86 mg/kg,
Fatal Plus, Vortech Pharmaceuticals, Dearborn, MI) one at six
Figure 1. Comparison of GFP expression in scAAV2/5 and ssAAV2/5 injected eyes (dog 1). A: Pre-INJ shows the fundus appearance before
subretinal injection. post-INJ images were taken immediately after subretinal injection and show the resulting retinal detachment. The images
day 6 to day 54 were taken using identical fluorescein angiography settings. The lower images (day 6 and 11 for scAAV2/5 and day 6 to 54
for ssAAV2/5) were adjusted for brightness and contrast to the same degree. GFP expression in the scAAV2/5 injected eye was detectable
from day 6 whereas in the ssAAV2/5 injected eye it was not apparent until day 32. GFP expression was stronger in the scAAV2/5 injected eye.
B: Comparison of GFP fluorescence in retinal cross sections from the center of the injected regions of both eyes of dog 1 (obtained with
identical microscope and camera settings). Scale bar equals 50 µm.
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1837and the other at seven months following subretinal injections.
The globes were immediately removed and slits were made
through  pars  plana  into  the  vitreous.  The  globes  were
immersed for 15 min at 4 °C in 4% paraformaldehyde plus 3%
sucrose in 0.1M phosphate buffered saline (PBS; 50 mM
sodium  phosphate,  195  mM  NaCl;  pH  7.4).  The  anterior
segment was then removed and the posterior eyecup returned
to the same fixative for 20 min, then washed three times for
30 s in fresh PBS at 4 °C. The eyecup was placed in PBS plus
30% sucrose for 24 h then immersed in embedding medium
(Tissue-Tek  OCT  compound,  Sakura  Finetek  USA  Inc.,
Torrance, CA).
From  the  OCT  blocks  14  μm  sections  were  cut  in  a
vertical plane through the optic nerve head and thaw-mounted
onto  Super-FrostTM  slides  (Fisher  Scientific  Ltd,
Leicestershire, UK), air-dried and stored at −20 °C until use.
Primary antibodies used are listed in Table 1. Sections
were incubated for 24 h at 20 °C in a humidified chamber. The
slides were washed in PBS, covered with secondary antibody
solution, and incubated for 1 h at 20 °C in a humidified
chamber.  Secondary  antibodies  included  goat-anti-rabbit-
Alexa488  and  goat-anti-mouse  Alexa568/647  (Molecular
Probes Inc., Eugene, OR).
Photomicrographs were taken using a Leica DM5000B
microscope  equipped  with  epifluorescence  and  a  12
megapixel  Leica  DC500  digital  camera.  Images  were
optimized for color, brightness, and contrast, and double-
labeled images overlaid by using PhotoshopTM 6.0. (Adobe
Systems Inc.). Confocal imaging was done using a Zeiss LSM
510 system at the Hunt-Curtis Microscopy Facility at The
Ohio State University.
RESULTS
Rate and strength of GFP expression: Following subretinal
injection the retina was found to have reattached by two days
postinjection  in  all  eyes.  As  expected,  there  was  a  mild
surgically induced intraocular inflammatory reaction in all
four eyes that resolved within the first week. Both eyes of one
dog  showed  ophthalmoscopic  evidence  of  mild  retinal
Figure  2.  Immunohistochemical
investigation  of  retinal  cell  type
expressing  GFP.  A  to  C  are
conventional  fluorescent  microscopy
images  and  D  to  F  are  confocal
microscopy images. A and B: Sections
through  the  ssAAV2/5  injected  eye
from the peripheral retina away for the
injection  site  (A)  and  through  the
injection site (B). C: A section through
the injection site in a scAAV2/5 injected
eye. D: A section through the injected
region of a scAAV2/5 eye. The Z stack
is shown on the right. Co-localization of
hCAR  immunoreactivity  and  GFP
expression is present in some, but not all
of  the  cone  photoreceptors.  Arrows
indicate two hCAR positive cones that
do  not  have  observable  endogenous
GFP expression. E: The rod bipolar cells
(which  are  PKC  immunoreactive)  are
not  expressing  GFP.  F:  There  is  co-
localization  of  GFP  expression  and
PSD95  immunoreactivity  in
photoreceptor terminals. Abbreviations:
ONL, outer nuclear layer ; INL, inner
nuclear layer; GCL, ganglion cell layer,
PKC, protein kinase C (rod bipolar cell
marker); hCAR, human cone arrestin (a
cone marker); GFP, green fluorescent
protein; PSD95, post synaptic density
protein 95 (a marker for rod and cone
spherules). Scale bar equals 50 μm.
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1838inflammation with engorgement of retinal vasculature. This
resolved within one week. No medical therapy was required.
GFP expression as monitored ophthalmoscopically had a
similar pattern in both dogs. Fluorescence in the scAAV2/5-
GFP-injected eyes was apparent much sooner after injection
and  was  notably  stronger  compared  to  that  seen  in  the
ssAAV2/5-injected  eyes.  In  the  scAAV2/5-GFP-injected
eyes,  faint  GFP  expression  was  evident  at  six  days
postinjection and was clearly visible by 11 days postinjection
(Figure  1).  The  brightness  of  the  fluorescence  further
increased over the following two weeks and then remained
stable for the duration of the study. The ssAAV2/5 GFP-
injected eyes had weaker GFP expression. GFP expression in
these eyes was not apparent ophthalmoscopically until 32
days after injection. GFP expression increased until day 54
and then remained stable for the duration of the study. The
strength of GFP expression seen in the histological sections
through  the  injected  areas  reflected  the  stronger  GFP
expression in the scAAV2/5-GFP injected eyes compared to
the ssAAV2/5-GFP eyes that was apparent in vivo (Figure 1).
Cells targeted by ssAAV2/5 and scAAV2/5: Retinal pigment
epithelium  (not  shown)  and  photoreceptors  in  ssAAV2/5-
injected and scAAV2/5-injected eyes expressed GFP (Figure
1B, Figure 2B-F, Figure 3, and Figure 4). Rod cell bodies and
inner  and  outer  segments  clearly  expressed  GFP.  In  both
ssAAV2/5- and scAAV2/5-injected eyes some cones in the
transduced areas did not express GFP. To further assess cone
GFP  expression,  we  used  a  human  cone  arrestin  (hCAR)
antibody that marks the entire cone cell body (Figure 2A-C).
This  confirmed  that  within  the  transduced  region,  GFP
expression  was  not  detectable  in  all  cones  (cones  not
expressing GFP at detectable levels are indicated by arrows
in Figure 2D). To assess the proportion of GFP-expressing
cones,  we  counted  the  number  of  GFP-positive  hCAR
immunoreactive cone photoreceptors across sections of the
injected area of one of the scAAV2/5 treated retinas. Of 92
consecutive hCAR immunoreactive cones, 55 had clear GFP
expression.
Some  inner  retinal  cells  were  transduced  in  both
scAAV2/5-  and  ssAAV2/5-injected  eyes.  Immunostaining
with protein kinase C alpha that detects rod ON bipolar cells
did not identify any that had been transduced (Figure 2). Using
conventional fluorescence microscopy, we found it was not
possible to differentiate between expression in photoreceptor
end terminals and in bipolar cell dendrites (see Figure 2C).
Confocal microscopy provided the resolution to show that
GFP expression was absent from rod bipolar cell dendrites
(see Figure 2E for an example). Immunostaining with PSD95
confirmed that there was GFP expression in the photoreceptor
synaptic terminals (Figure 2F). Further investigation of the
inner  retinal  cells  expressing  GFP  showed  that  some
horizontal cells (Figure 3A) and Müller cells (Figure 3B) were
also transduced. Immunostaining with an anti-GFP antibody
made it possible to detect inner retinal GFP expression in the
ssAAV2/5-injected retinas. The stronger expression of GFP
in scAAV2/5-injected retinas meant that they did not require
immunostaining for GFP to enhance detection.
Glial fibrillary acidic protein (GFAP) staining did not
reveal any appreciable difference in GFAP expression in glia
in the transduced regions compared to areas of retina outside
of the transduced region in either ssAAV2/5- or scAAV2/5-
injected  eyes  (Figure  4).  GFAP  immunoreactivity  was
confined to astrocytes in inner retinal layers. There was no
indication of reactive (GFAP expressing) Müller glia.
DISCUSSION
Subretinal injection of an scAAV2/5 vector in the dog results
in  stronger  reporter  gene  expression  compared  to  that
produced by a single-stranded version of the vector at the same
titer  and  volume  of  injection.  GFP  expression  could  be
detected  on  ophthalmoscopic  examination  six  days  after
injection in the scAAV2/5-injected eyes compared to 32 days
in  the  ssAAV2/5-injected  eyes.  Once  fluorescence  levels
Figure  3.  AAV2/5-GFP  transduction
includes  a  few  horizontal  cells  and
Müller glia. A: The panel shows native
GFP  fluorescence  (scAAV2/5-GFP-
injected retina), calbindin and calretinin
immunohistochemistry and a merge of
all  three.  The  arrow  indicates  a
horizontal cell that is expressing GFP.
B:  The  image  on  the  left  shows
endogenous  GFP  expression;  some
inner retinal cells are expressing GFP
(ssAAV2/5-GFP-injected  retina).  The
image  on  the  right  shows
immunohistochemistry  using  an  anti-
GFP  antibody.  The  arrows  indicate
Müller cells that are expressing GFP.
Scale bar equals 50 µm.
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1839peaked, they remained stable for all injected eyes (scAAV2/5
and ssAAV2/5) for the duration of the study. These findings
are  similar  to  mouse  studies  that  compared  retinal
transduction with scAAV2/5 versus ssAAV2/5 vectors [18].
Natkunarajah et al. monitored reporter gene expression by
funduscopic examination following injection of an AAV2/8,
either with a single copy of the reporter gene (ssAAV2/8) or
a sc construct (scAAV2/8), and found stronger reporter gene
expression  with  the  scAAV2/8  vector  compared  to  the
ssAAV2/8 [19]. Using either ss or sc AAV2-GFP vectors,
with fluorescence assessment at the cell-level, Yokoi et al.
found  earlier  and  stronger  expression  in  photoreceptors
following subretinal injection of the scAAV2 compared to the
ssAAV2 [18]. They also demonstrated that GFP expression in
retinal  pigment  epithelium  occurred  before  that  in
photoreceptors.  With  the  design  of  our  study,  it  was  not
possible to assess any difference in the rate of gene expression
between different retinal cell types. The difference in rate of
GFP expression seen between the scAAV2/5-injected eyes
and the ssAAV2/5-injected eyes may be either because of the
faster expression expected from an sc construct or as a result
of the much stronger expression induced by this vector, or a
combination of both factors. The current study only used a
single titer of the vectors. It is possible that if the vector titer
were increased, the difference in onset and strength of reporter
gene  expression  between  the  two  vector  types  might  be
diminished.  Additional  experiments  would  be  required  to
investigate this possibility and to optimize vector titer for the
two vector types such that all rods and a high proportion of
cones were transduced across the injected region. The volume
of injection was selected because in previous studies we found
that it was sufficient to cause a detachment of about one-
quarter of the retina and yet allow the retina to reattach within
one or two days postinjection.
Despite uniform strong expression in rod photoreceptors
across  the  injected  area,  only  about  60%  of  cone
photoreceptors expressed GFP. This appears to be a greater
proportion of cones than previously recorded in a study using
an AAV2 vector expressing GFP under the CMV promoter
[22]. In that study, only 5% to 10% of cones were transduced,
compared to a high percentage of rods. Although we did not
attempt to investigate whether there was a difference in GFP
expression between L/M, and S cones, it is of interest that an
S-cone promoter that had been successfully used in the rat
[23] failed to transduce S-cone photoreceptors in the dog
[24]. The proportion of S-cones in the dogs is between 9% and
18% [25]. Thus, it seems unlikely that a lack of expression in
S-cones alone accounts for the cones in our study that did not
express  GFP.  Clearly  further  vector  and  promoter
development is required to optimize the targeting of cones in
the dog.
Some inner retinal neurons were found to express GFP in
this study, although AAV2/5 has not been reported to target
inner retinal cells efficiently [26]. In addition, expression in
Figure  4.  Investigation  of  GFAP
expression  in  the  injected  retina.  The
expression  of  GFAP  was  similar
between transduced (lower panel) and
non-transduced (upper panel) regions of
scAAV2/5-injected eyes. The similarity
in GFAP immunoreactivity between the
injected  and  non-injected  areas
indicates that expression of GFP is not
inducing glial cell reactivity. Scale bar
equals 25 µm.
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1840some Müller cells was seen. Access of the vector to inner
retinal cells may have been from the subretinal space or it is
possible that there was some reflux of viral particles through
the retinotomy site into the vitreous allowing access from the
vitreal surface. A previous study delivering AAV2-GFP by
subretinal injection in dogs reported ganglion cell expression
of GFP. It was thought that the vector reached the ganglion
cells due to reflux into the vitreous through the retinotomy site
[22]. We found a few examples of transduced horizontal cells,
whereas bipolar cells were not transduced.
This  study  showed  that  scAAV2/5-GFP  delivered  by
subretinal  injection  in  the  dog  results  in  funduscopically
detectable  GFP  protein  levels  much  more  rapidly  than
achieved with an ssAAV2/5 construct. Thus scAAV vectors
show  promise  for  the  treatment  of  rapid  onset  retinal
dystrophies  where  speed  of  transgene  expression  may  be
critical. The stronger level of expression achieved with the
scAAV vector may also mean that lower titers of scAAV
compared  to  ssAAV  achieve  the  same  level  of  transgene
expression perhaps reducing the risk of adverse effects due to
immune  responses  to  the  vector  itself.  Unfortunately,  the
relatively  limited  packaging  capacity  of  AAV  vectors
(typically stated to be 4.7 kb) will limit the size of transgene
that  can  be  packaged  in  a  self-complementary  manner.
However, a recent report suggested that AAV5 capsids could
be efficiently packaged with up to 8.9 kb of transgene [27].
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